 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- LCAR-M23 / Legend Biotech
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer (clinicaltrials.gov) - Aug 18, 2022
P1, N=15, Terminated, Sponsor: Shanghai East Hospital
N=34 --> 15 | Trial completion date: Nov 2024 --> Jun 2022 | Recruiting --> Terminated | Trial primary completion date: Nov 2022 --> Jun 2022; Both the sponsors and collaborator are considering terminating the study.
- || LCAR-M23 / Legend Biotech
Enrollment open: A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer (clinicaltrials.gov) - Nov 12, 2020
P1, N=34, Recruiting, Sponsor: Shanghai East Hospital
N=34 --> 15 | Trial completion date: Nov 2024 --> Jun 2022 | Recruiting --> Terminated | Trial primary completion date: Nov 2022 --> Jun 2022; Both the sponsors and collaborator are considering terminating the study. Not yet recruiting --> Recruiting
- || LCAR-M23 / Legend Biotech
New P1 trial: A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-M23, a CAR-T Cell Therapy Targeting MSLN in Patients With Relapsed and Refractory Epithelial Ovarian Cancer (clinicaltrials.gov) - Sep 23, 2020
P1, N=34, Not yet recruiting, Sponsor: Shanghai East Hospital